Recombinant SARS-CoV-2 S1 protein NTD (L18F, D80A, D215G, 242-244del, R246I), His Tag (MALS verified), 100µg

Background
It's been reported that Coronavirus can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.

Source
Recombinant SARS-CoV-2 S1 protein NTD, His Tag (S1D-C52Hc) is expressed from human 293 cells (HEK293). It contains AA Ser 13 - Leu 303 (Accession # QHD43416.1). The L18F/D80A/D215G/LAL242-244del/R246I mutations were identified on the spike protein N-terminal domain (NTD) in the SARS-CoV-2 Beta variant (Pango lineage: B.1.351; other names: 20H/501Y.V2).
Predicted N-terminus: Ser 13

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 34.5 kDa. The protein migrates as 50-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Two Receptor Binding Strategy of SARS-CoV-2 Is Mediated by Both the N-Terminal and Receptor-Binding Spike Domain"
Monti, Milanetti, Frans et al
J Phys Chem B (2024)
(2) "Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques"
Sankhala, Lal, Jensen et al
Nat Commun (2024) 15 (1), 200
(3) "Enhancement of SARS-CoV-2 Infection via Crosslinking of Adjacent Spike Proteins by N-Terminal Domain-Targeting Antibodies"
Lusiany, Terada, Kishikawa et al
Viruses (2023) 15 (12)
Showing 1-3 of 351 papers